|
US3598122A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3993073A
(en)
|
1969-04-01 |
1976-11-23 |
Alza Corporation |
Novel drug delivery device
|
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US4069307A
(en)
|
1970-10-01 |
1978-01-17 |
Alza Corporation |
Drug-delivery device comprising certain polymeric materials for controlled release of drug
|
|
US3731683A
(en)
|
1971-06-04 |
1973-05-08 |
Alza Corp |
Bandage for the controlled metering of topical drugs to the skin
|
|
US3742951A
(en)
|
1971-08-09 |
1973-07-03 |
Alza Corp |
Bandage for controlled release of vasodilators
|
|
US3996934A
(en)
|
1971-08-09 |
1976-12-14 |
Alza Corporation |
Medical bandage
|
|
BE795384A
(fr)
|
1972-02-14 |
1973-08-13 |
Ici Ltd |
Pansements
|
|
US3921636A
(en)
|
1973-01-15 |
1975-11-25 |
Alza Corp |
Novel drug delivery device
|
|
US3993072A
(en)
|
1974-08-28 |
1976-11-23 |
Alza Corporation |
Microporous drug delivery device
|
|
US4151273A
(en)
|
1974-10-31 |
1979-04-24 |
The Regents Of The University Of California |
Increasing the absorption rate of insoluble drugs
|
|
US3972995A
(en)
|
1975-04-14 |
1976-08-03 |
American Home Products Corporation |
Dosage form
|
|
US4077407A
(en)
|
1975-11-24 |
1978-03-07 |
Alza Corporation |
Osmotic devices having composite walls
|
|
US4031894A
(en)
|
1975-12-08 |
1977-06-28 |
Alza Corporation |
Bandage for transdermally administering scopolamine to prevent nausea
|
|
US4060084A
(en)
|
1976-09-07 |
1977-11-29 |
Alza Corporation |
Method and therapeutic system for providing chemotherapy transdermally
|
|
US4201211A
(en)
|
1977-07-12 |
1980-05-06 |
Alza Corporation |
Therapeutic system for administering clonidine transdermally
|
|
JPS5562012A
(en)
|
1978-11-06 |
1980-05-10 |
Teijin Ltd |
Slow-releasing preparation
|
|
US4230105A
(en)
|
1978-11-13 |
1980-10-28 |
Merck & Co., Inc. |
Transdermal delivery of drugs
|
|
US4229447A
(en)
|
1979-06-04 |
1980-10-21 |
American Home Products Corporation |
Intraoral methods of using benzodiazepines
|
|
CA1146866A
(en)
|
1979-07-05 |
1983-05-24 |
Yamanouchi Pharmaceutical Co. Ltd. |
Process for the production of sustained release pharmaceutical composition of solid medical material
|
|
US4291015A
(en)
|
1979-08-14 |
1981-09-22 |
Key Pharmaceuticals, Inc. |
Polymeric diffusion matrix containing a vasodilator
|
|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US4596795A
(en)
|
1984-04-25 |
1986-06-24 |
The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services |
Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
|
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
|
GB8518301D0
(en)
|
1985-07-19 |
1985-08-29 |
Fujisawa Pharmaceutical Co |
Hydrodynamically explosive systems
|
|
US5011692A
(en)
|
1985-12-28 |
1991-04-30 |
Sumitomo Pharmaceuticals Company, Limited |
Sustained pulsewise release pharmaceutical preparation
|
|
US4755386A
(en)
|
1986-01-22 |
1988-07-05 |
Schering Corporation |
Buccal formulation
|
|
US5312325A
(en)
|
1987-05-28 |
1994-05-17 |
Drug Delivery Systems Inc |
Pulsating transdermal drug delivery system
|
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
US5739136A
(en)
|
1989-10-17 |
1998-04-14 |
Ellinwood, Jr.; Everett H. |
Intraoral dosing method of administering medicaments
|
|
US5017381A
(en)
|
1990-05-02 |
1991-05-21 |
Alza Corporation |
Multi-unit pulsatile delivery system
|
|
US5633009A
(en)
|
1990-11-28 |
1997-05-27 |
Sano Corporation |
Transdermal administration of azapirones
|
|
KR0182801B1
(ko)
|
1991-04-16 |
1999-05-01 |
아만 히데아키 |
고체 분산체의 제조방법
|
|
CZ282760B6
(cs)
|
1991-11-22 |
1997-09-17 |
Procter And Gamble Pharmaceuticals, Inc. |
Risedronátové prostředky se zpožděným uvolňováním
|
|
US5229135A
(en)
|
1991-11-22 |
1993-07-20 |
Prographarm Laboratories |
Sustained release diltiazem formulation
|
|
US5340591A
(en)
|
1992-01-24 |
1994-08-23 |
Fujisawa Pharmaceutical Co., Ltd. |
Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
|
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
|
US5260068A
(en)
|
1992-05-04 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Multiparticulate pulsatile drug delivery system
|
|
US5281420A
(en)
|
1992-05-19 |
1994-01-25 |
The Procter & Gamble Company |
Solid dispersion compositions of tebufelone
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
AU4198793A
(en)
|
1992-07-24 |
1994-01-27 |
Takeda Chemical Industries Ltd. |
Microparticle preparation and production thereof
|
|
US5700485A
(en)
|
1992-09-10 |
1997-12-23 |
Children's Medical Center Corporation |
Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
|
|
DE69332291T2
(de)
|
1992-10-16 |
2003-07-31 |
Nippon Shinyaku Co., Ltd. |
Verfahren zur herstellung von wachsmatrizes
|
|
US5260069A
(en)
|
1992-11-27 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Pulsatile particles drug delivery system
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
US5665378A
(en)
|
1994-09-30 |
1997-09-09 |
Davis; Roosevelt |
Transdermal therapeutic formulation
|
|
US5567441A
(en)
|
1995-03-24 |
1996-10-22 |
Andrx Pharmaceuticals Inc. |
Diltiazem controlled release formulation
|
|
JPH11505258A
(ja)
|
1995-05-17 |
1999-05-18 |
セダーシナイ メディカル センター |
小腸における消化および吸収を改善させる脂肪酸を含む組成物
|
|
SE9502244D0
(sv)
|
1995-06-20 |
1995-06-20 |
Bioglan Ab |
A composition and a process for the preparation thereof
|
|
US5837284A
(en)
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
|
US5858401A
(en)
|
1996-01-22 |
1999-01-12 |
Sidmak Laboratories, Inc. |
Pharmaceutical composition for cyclosporines
|
|
US6923983B2
(en)
|
1996-02-19 |
2005-08-02 |
Acrux Dds Pty Ltd |
Transdermal delivery of hormones
|
|
US6929801B2
(en)
|
1996-02-19 |
2005-08-16 |
Acrux Dds Pty Ltd |
Transdermal delivery of antiparkinson agents
|
|
US6458373B1
(en)
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
|
US5840329A
(en)
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
US5869090A
(en)
|
1998-01-20 |
1999-02-09 |
Rosenbaum; Jerry |
Transdermal delivery of dehydroepiandrosterone
|
|
US6946144B1
(en)
|
1998-07-08 |
2005-09-20 |
Oryxe |
Transdermal delivery system
|
|
EP1027886B1
(en)
|
1999-02-10 |
2008-07-09 |
Pfizer Products Inc. |
Pharmaceutical solid dispersions
|
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
|
JP2003504401A
(ja)
|
1999-07-16 |
2003-02-04 |
ワーナー−ランバート・カンパニー |
Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
|
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
|
JP2002309116A
(ja)
|
2001-04-09 |
2002-10-23 |
Fuji Photo Film Co Ltd |
アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
|
|
JP4406515B2
(ja)
|
2001-04-09 |
2010-01-27 |
富士フイルム株式会社 |
アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
|
|
KR100601775B1
(ko)
|
2001-04-09 |
2006-07-19 |
후지 샤신 필름 가부시기가이샤 |
화상 형성용 착색 조성물 및 칼라 화상의 내오존성 개선방법
|
|
US6960563B2
(en)
|
2001-08-31 |
2005-11-01 |
Morton Grove Pharmaceuticals, Inc. |
Spontaneous emulsions containing cyclosporine
|
|
JP2003292859A
(ja)
|
2002-01-30 |
2003-10-15 |
Fuji Photo Film Co Ltd |
インク組成物、インクジェット記録方法
|
|
JP3844338B2
(ja)
|
2002-02-01 |
2006-11-08 |
富士写真フイルム株式会社 |
インクセット、インクカートリッジ、記録方法、プリンター及び記録物
|
|
JP2004059687A
(ja)
|
2002-07-26 |
2004-02-26 |
Fuji Photo Film Co Ltd |
着色組成物、インクジェット記録用インク、インクジェット記録方法、感熱記録材料、カラートナー、およびカラーフィルター
|
|
JP4213922B2
(ja)
|
2002-08-12 |
2009-01-28 |
富士フイルム株式会社 |
インクジェット記録用インク及びインクセット、並びにインクジェット記録方法
|
|
JP2004083610A
(ja)
|
2002-08-22 |
2004-03-18 |
Fuji Photo Film Co Ltd |
インクセット、インクカートリッジ、記録方法、プリンター及び記録物
|
|
JP2004099802A
(ja)
|
2002-09-11 |
2004-04-02 |
Fuji Photo Film Co Ltd |
画像形成用着色組成物、インクジェット記録用インクおよびインクジェット記録方法
|
|
JP4895341B2
(ja)
|
2004-07-08 |
2012-03-14 |
富士フイルム株式会社 |
アゾ色素、インクジェット記録用インク、感熱記録材料、カラートナー、カラーフィルター、インクジェット記録方法、インクカートリッジ及びインクジェットプリンター
|
|
JP5241513B2
(ja)
|
2006-01-26 |
2013-07-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アミノクロトニルアミノ置換キナゾリン誘導体の合成方法
|
|
JP2007203642A
(ja)
|
2006-02-02 |
2007-08-16 |
Fujifilm Corp |
インクジェット記録用セット、及びインクジェット記録方法
|
|
JP2008013499A
(ja)
|
2006-07-06 |
2008-01-24 |
Sankyo Co Ltd |
５−シアノニコチンアミド誘導体
|
|
US7741385B2
(en)
|
2006-10-31 |
2010-06-22 |
Hewlett-Packard Development Company, L.P. |
Ozone stable ink-jet inks
|
|
JP2009139810A
(ja)
|
2007-12-10 |
2009-06-25 |
Konica Minolta Business Technologies Inc |
電子写真用トナー
|
|
SI2428508T1
(sl)
|
2009-05-08 |
2016-04-29 |
Astellas Pharma Inc. |
Diamino heterociklična karboksamidna spojina
|
|
US8722930B2
(en)
|
2009-05-18 |
2014-05-13 |
Orion Corporation |
Protease inhibitors
|
|
AR078173A1
(es)
|
2009-09-15 |
2011-10-19 |
Sanofi Aventis |
Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso
|
|
WO2012002577A1
(ja)
|
2010-06-30 |
2012-01-05 |
富士フイルム株式会社 |
新規なニコチンアミド誘導体またはその塩
|
|
JP2014005206A
(ja)
|
2010-10-22 |
2014-01-16 |
Astellas Pharma Inc |
アリールアミノヘテロ環カルボキサミド化合物
|
|
EP2635556B1
(en)
|
2010-11-01 |
2017-06-21 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as syk modulators
|
|
DK2799431T3
(en)
|
2011-12-28 |
2018-03-26 |
Fujifilm Corp |
Hitherto unknown nicotinamide derivatives or salts thereof
|
|
PL2805940T3
(pl)
|
2012-01-17 |
2017-06-30 |
Astellas Pharma Inc. |
Związek pirazynokarboksyamidowy
|
|
EP2828259B1
(en)
|
2012-03-22 |
2018-08-08 |
Oscotec, Inc. |
Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
|
|
PT2840080T
(pt)
|
2012-04-17 |
2018-02-06 |
Fujifilm Corp |
Composto heterocíclico que contém azoto ou sal do mesmo
|
|
CN103732575A
(zh)
|
2012-07-20 |
2014-04-16 |
中国人民解放军军事医学科学院毒物药物研究所 |
间二芳基苯胺类或吡啶胺类化合物、其制备方法及医药用途
|
|
CN105683167B
(zh)
|
2013-10-16 |
2018-10-23 |
富士胶片株式会社 |
含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
|
|
WO2015062929A1
(en)
|
2013-10-29 |
2015-05-07 |
Dystar Colours Distribution Gmbh |
Acid dyes, process for the production thereof and their use
|
|
EP2868710A1
(en)
|
2013-10-29 |
2015-05-06 |
DyStar Colours Distribution GmbH |
Metal free acid dyes, process for the production thereof and their use
|
|
EP2868709A1
(en)
|
2013-10-29 |
2015-05-06 |
DyStar Colours Distribution GmbH |
Metal free acid dyes, process for the production thereof and their use
|
|
US20200332369A1
(en)
|
2014-01-27 |
2020-10-22 |
Dna-Seq, Inc. |
Methods and systems for determination of an effective therapeutic regimen and drug discovery
|
|
CA2938818C
(en)
|
2014-02-04 |
2023-03-07 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
|
|
EP3150206A1
(en)
|
2014-05-28 |
2017-04-05 |
Astellas Pharma Inc. |
Medicinal composition comprising pyrazine carboxamide compound as active ingredient
|
|
JP6665154B2
(ja)
|
2014-07-17 |
2020-03-13 |
ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド |
置換尿素誘導体及びその薬学的使用
|
|
KR20170032244A
(ko)
|
2014-07-26 |
2017-03-22 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
|
|
CN105294655B
(zh)
|
2014-07-26 |
2019-03-15 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
CN105439879B
(zh)
|
2014-08-07 |
2018-08-10 |
天津法莫西医药科技有限公司 |
一种反式-4-二甲胺基巴豆酸盐酸盐的制备方法
|
|
WO2016023217A1
(zh)
|
2014-08-15 |
2016-02-18 |
安润医药科技（苏州）有限公司 |
喹唑啉衍生物、其制备方法、药物组合物和应用
|
|
WO2016027904A1
(ja)
|
2014-08-22 |
2016-02-25 |
富士フイルム株式会社 |
Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
|
|
ES2834618T3
(es)
|
2014-12-18 |
2021-06-18 |
Aravive Biologics Inc |
Actividad antifibrótica del inhibidor de GAS6
|
|
WO2016121777A1
(ja)
|
2015-01-28 |
2016-08-04 |
アステラス製薬株式会社 |
ピラジンカルボキサミド化合物の製造方法及びその合成中間体
|
|
EP3290036A4
(en)
|
2015-04-27 |
2019-01-02 |
Astellas Pharma Inc. |
Stabilized pharmaceutical composition
|
|
JP2018104290A
(ja)
|
2015-04-28 |
2018-07-05 |
アステラス製薬株式会社 |
ピラジンカルボキサミド化合物を有効成分とする医薬組成物
|
|
CN106267234B
(zh)
|
2015-06-26 |
2020-04-10 |
上海市计划生育科学研究所 |
含有非核苷类逆转录酶抑制剂的阴道环及其制备方法
|
|
EP3316888A1
(en)
|
2015-07-02 |
2018-05-09 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
|
FI3318259T3
(fi)
|
2015-07-03 |
2023-03-20 |
Astellas Pharma Inc |
Stabiili farmaseuttinen koostumus annettavaksi suun kautta
|
|
JP6412471B2
(ja)
|
2015-07-15 |
2018-10-24 |
富士フイルム株式会社 |
含窒素複素環化合物の製造方法およびその中間体
|
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
|
CN106588943B
(zh)
|
2015-10-19 |
2018-10-16 |
广东东阳光药业有限公司 |
一种egfr抑制剂的盐、晶型及其用途
|
|
ES2894691T3
(es)
|
2015-11-04 |
2022-02-15 |
Astellas Pharma Inc |
Composición farmacéutica para propósitos de inmunoterapia y/o inmunoestimulación que contiene compuesto heterocíclico de diamino-carboxamida como principio activo
|
|
CN108778260A
(zh)
|
2015-11-11 |
2018-11-09 |
塞拉特药物股份有限公司 |
选择白血病对象的治疗方案的分析和方法
|
|
JP6921818B2
(ja)
|
2015-11-14 |
2021-08-18 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． |
置換キノリン化合物の結晶形およびその医薬組成物
|
|
WO2017083789A1
(en)
|
2015-11-14 |
2017-05-18 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
JP2019014653A
(ja)
|
2015-11-27 |
2019-01-31 |
アステラス製薬株式会社 |
がん免疫を介したがん治療方法
|
|
TWI623316B
(zh)
|
2015-12-22 |
2018-05-11 |
Taiho Pharmaceutical Co Ltd |
Antitumor effect enhancer derived from pyrrolopyrimidine compound
|
|
ES2912909T3
(es)
|
2016-02-26 |
2022-05-30 |
Celgene Corp |
Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
|
|
JP2019512495A
(ja)
|
2016-03-29 |
2019-05-16 |
アステラス製薬株式会社 |
急性骨髄性白血病の治療のための併用療法
|
|
CN109562176A
(zh)
|
2016-04-15 |
2019-04-02 |
费利克斯疗法公司 |
使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
|
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
|
WO2017214433A1
(en)
|
2016-06-09 |
2017-12-14 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
|
|
WO2017218365A1
(en)
|
2016-06-16 |
2017-12-21 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
CN106083821B
(zh)
|
2016-06-22 |
2019-01-11 |
上海皓元生物医药科技有限公司 |
一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法
|
|
HUE059242T2
(hu)
|
2016-07-29 |
2022-11-28 |
Rapt Therapeutics Inc |
Azetidin-származékok mint kemokin receptor modulátorok és felhasználásuk
|
|
US10246462B2
(en)
|
2016-09-09 |
2019-04-02 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
|
US10111882B2
(en)
|
2016-09-14 |
2018-10-30 |
Gilead Sciences, Inc. |
SYK inhibitors
|
|
US11672801B2
(en)
|
2016-10-19 |
2023-06-13 |
United States Government As Represented By The Department Of Veterans Affairs |
Compositions and methods for treating cancer
|
|
JPWO2018079570A1
(ja)
|
2016-10-26 |
2019-09-19 |
アステラス製薬株式会社 |
安定な医薬組成物
|
|
CN106589055B
(zh)
|
2016-11-03 |
2020-07-28 |
清华大学 |
取代的细胞酰二肽类化合物及其制备方法和用途
|
|
AR110273A1
(es)
|
2016-11-30 |
2019-03-13 |
Pharmacyclics Llc |
Inhibidores de tirosina cinasa de bruton
|
|
CN108419436B
(zh)
|
2016-12-09 |
2021-05-04 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
|
|
CN108250200A
(zh)
|
2016-12-28 |
2018-07-06 |
中国科学院上海药物研究所 |
一种具有Axl抑制活性的化合物及其制备和应用
|
|
TWI808958B
(zh)
|
2017-01-25 |
2023-07-21 |
美商特普醫葯公司 |
涉及二芳基巨環化合物之組合療法
|
|
US20180344702A1
(en)
|
2017-02-21 |
2018-12-06 |
Aptose Biosciences Inc. |
Methods for treating patients with hematologic malignancies
|
|
GB201704267D0
(en)
|
2017-03-17 |
2017-05-03 |
Genome Res Ltd |
Novel biomarker
|
|
WO2018175251A1
(en)
|
2017-03-20 |
2018-09-27 |
Celcuity Llc |
Methods of measuring signaling pathway activity for selection of therapeutic agents
|
|
WO2018183762A1
(en)
|
2017-03-29 |
2018-10-04 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating cancer
|
|
CA3052543A1
(en)
|
2017-03-31 |
2018-10-04 |
Novartis Ag |
Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
|
|
ES2977788T3
(es)
|
2017-04-20 |
2024-08-30 |
Adc Therapeutics Sa |
Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
|
|
CN110621316B
(zh)
|
2017-04-21 |
2024-01-26 |
Epizyme股份有限公司 |
用ehmt2抑制剂进行的组合疗法
|
|
WO2018200465A1
(en)
|
2017-04-24 |
2018-11-01 |
Ohio State Innovation Foundation |
Recombinant egfl7, egfl7 antibodies, and uses thereof
|
|
US10857144B2
(en)
|
2017-05-16 |
2020-12-08 |
Bow River LLC |
Methods of treatment
|
|
WO2018211018A1
(en)
|
2017-05-17 |
2018-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
|
CN118772278A
(zh)
|
2017-06-02 |
2024-10-15 |
辉瑞公司 |
Flt3的特异性抗体及其用途
|
|
WO2019012328A1
(en)
|
2017-07-09 |
2019-01-17 |
Biosight Pharma |
ANTICANCER POLY THERAPY
|
|
CN109251182A
(zh)
|
2017-07-13 |
2019-01-22 |
广东东阳光药业有限公司 |
取代脲衍生物的盐及其在药物中的应用
|
|
US11286264B2
(en)
|
2017-07-28 |
2022-03-29 |
Turning Point Therapeutics, Inc. |
Macrocyclic compounds and uses thereof
|
|
JP7156287B2
(ja)
|
2017-08-23 |
2022-10-19 |
小野薬品工業株式会社 |
Ａｘｌ阻害剤を有効成分として含むがん治療剤
|
|
JP2020535173A
(ja)
|
2017-09-27 |
2020-12-03 |
エイアイ・セラピューティクス・インコーポレーテッド |
Ｈｓｐ９０阻害剤に関係する治療方法
|
|
CA3019207A1
(en)
|
2017-09-28 |
2019-03-28 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant egfr signaling
|
|
IL273824B2
(en)
|
2017-10-18 |
2024-07-01 |
Epizyme Inc |
Methods for using EHMT2 inhibitors in the treatment or prevention of blood disorders
|
|
JP6915076B2
(ja)
|
2017-10-24 |
2021-08-04 |
京セラ株式会社 |
複合基板、およびそれを用いた弾性波素子
|
|
EP3700516B1
(en)
|
2017-10-27 |
2024-01-24 |
Sonic Master Limited |
Inhibitors of dux4 induction for regulation of muscle function
|
|
US11247990B1
(en)
|
2017-12-07 |
2022-02-15 |
Array Biopharma Inc |
Bicyclic fused pyridine compounds as inhibitors of TAM kinases
|
|
EP3752200A1
(en)
|
2018-02-13 |
2020-12-23 |
Vib Vzw |
Targeting minimal residual disease in cancer with rxr antagonists
|
|
GB201802307D0
(en)
|
2018-02-13 |
2018-03-28 |
Vib Vzw |
CD36 antagonists for use in melanoma treatment
|
|
WO2019178267A2
(en)
|
2018-03-13 |
2019-09-19 |
University Of Iowa Research Foundation |
Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
|
|
CN108392634A
(zh)
|
2018-03-28 |
2018-08-14 |
清华大学 |
B7s1抑制剂在制备肝癌药物中的用途
|
|
WO2019184966A1
(zh)
|
2018-03-28 |
2019-10-03 |
深圳市塔吉瑞生物医药有限公司 |
取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
|
|
WO2019197605A2
(en)
|
2018-04-12 |
2019-10-17 |
Umc Utrecht Holding B.V. |
Drug combinations for use in the treatment of ras-mutant cancer
|
|
WO2019245269A1
(ko)
|
2018-06-18 |
2019-12-26 |
연세대학교 산학협력단 |
Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물
|
|
EA202190181A1
(ru)
|
2018-07-04 |
2021-05-27 |
Сайтоиммьюн Терапьютикс, Инк. |
Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1
|
|
KR101954370B1
(ko)
|
2018-07-25 |
2019-03-05 |
한미약품 주식회사 |
피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
|
|
US12083136B2
(en)
|
2018-07-31 |
2024-09-10 |
Ascentage Pharma (Suzhou) Co., Ltd |
Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
|
|
KR20200022712A
(ko)
|
2018-08-23 |
2020-03-04 |
주식회사 오스코텍 |
8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
|
|
UY38349A
(es)
|
2018-08-30 |
2020-03-31 |
Array Biopharma Inc |
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
|
|
JP7201800B2
(ja)
|
2018-09-30 |
2023-01-10 |
メッドシャイン ディスカバリー インコーポレイテッド |
Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物
|
|
TW202027749A
(zh)
|
2018-10-12 |
2020-08-01 |
日商富士軟片股份有限公司 |
急性骨髓性白血病用抗腫瘤劑
|
|
WO2020090970A1
(ja)
|
2018-10-31 |
2020-05-07 |
富士フイルム株式会社 |
抗腫瘍剤を含む医薬組成物
|
|
JPWO2020090968A1
(ja)
|
2018-10-31 |
2021-09-16 |
富士フイルム株式会社 |
抗腫瘍剤を含む造粒物
|
|
EP3875089A4
(en)
|
2018-10-31 |
2021-12-22 |
FUJIFILM Corporation |
TABLET CONTAINING AN ANTI-TUMOR AGENT
|
|
JPWO2020090969A1
(ja)
|
2018-10-31 |
2021-09-16 |
富士フイルム株式会社 |
抗腫瘍剤を含む医薬組成物の包装体
|
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
CN113677346A
(zh)
|
2018-11-01 |
2021-11-19 |
希洛斯医药品股份有限公司 |
周期蛋白依赖性激酶7(cdk7)的抑制剂
|
|
WO2020118168A1
(en)
|
2018-12-07 |
2020-06-11 |
Cornell University |
Methods for detecting acute myeloid leukemia
|
|
US20200208114A1
(en)
|
2018-12-10 |
2020-07-02 |
The Broad Institute, Inc. |
Taxonomy and use of bone marrow stromal cell
|
|
WO2020122816A1
(en)
|
2018-12-12 |
2020-06-18 |
Agency For Science, Technology And Research |
Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof
|
|
TWI848030B
(zh)
|
2018-12-18 |
2024-07-11 |
比利時商阿根思公司 |
Ｃｄ７０組合治療
|
|
MX2021007391A
(es)
|
2018-12-20 |
2021-09-23 |
Novartis Ag |
Regimenes de baja dosis extendida para inhibidores de mdm2.
|
|
JPWO2020130125A1
(ja)
|
2018-12-21 |
2021-11-04 |
第一三共株式会社 |
抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
|
KR102230721B1
(ko)
|
2019-02-01 |
2021-03-22 |
주식회사 오스코텍 |
피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
|
|
WO2020172618A2
(en)
|
2019-02-21 |
2020-08-27 |
Bambu Vault Llc |
Remotely triggered therapy
|
|
WO2020171649A1
(ko)
|
2019-02-22 |
2020-08-27 |
한미약품 주식회사 |
Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
|
|
PH12021551985A1
(en)
|
2019-02-22 |
2022-08-22 |
Hanmi Pharmaceutical Co Ltd |
Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
|
|
US12472175B2
(en)
|
2019-02-26 |
2025-11-18 |
Oregon Health & Science University |
Methods of treating venetoclax-resistant acute myeloid leukemia
|
|
TW202045174A
(zh)
|
2019-02-28 |
2020-12-16 |
日商富士軟片股份有限公司 |
組合醫藥
|
|
JP7455810B2
(ja)
|
2019-03-13 |
2024-03-26 |
大塚製薬株式会社 |
二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
|
|
US20220143049A1
(en)
|
2019-03-21 |
2022-05-12 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
WO2020204142A1
(ja)
|
2019-04-03 |
2020-10-08 |
アステラス製薬株式会社 |
医薬組成物
|
|
EP3955928A4
(en)
|
2019-04-17 |
2023-05-31 |
Board of Regents, The University of Texas System |
COMPOUNDS HAVING ANTITUMORIC ACTIVITY AGAINST CANCER CELLS WITH TYROSINE KINAS INHIBITOR-RESISTANT EGFR MUTATIONS
|
|
SG11202111120VA
(en)
|
2019-04-17 |
2021-11-29 |
Univ Texas |
Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
|
|
WO2020219890A1
(en)
|
2019-04-25 |
2020-10-29 |
Ocular Therapeutix, Inc. |
Ocular hydrogel tyrosine kinase inhibitor implants
|
|
EP3965896A4
(en)
|
2019-05-09 |
2023-01-25 |
The United States Government as Represented by the Department of Veterans Affairs |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
|
BR112021025537A2
(pt)
|
2019-06-20 |
2022-03-03 |
Celgene Quanticel Res Inc |
Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
|
|
EA202290154A1
(ru)
|
2019-06-27 |
2022-03-29 |
Ханми Фарм. Ко., Лтд. |
Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
|
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
WO2021030642A1
(en)
|
2019-08-14 |
2021-02-18 |
Memorial Sloan Kettering Cancer Center |
Methods of treating p53 mutant cancers using ogdh inhibitors cross-reference to related applications
|
|
GB201912059D0
(en)
|
2019-08-22 |
2019-10-09 |
Bergenbio As |
Combaination therapy of a patient subgroup
|
|
GEP20247688B
(en)
|
2019-09-12 |
2024-11-11 |
Orion Corp |
Pyridine oxynitride, preparation method therefor and use thereof
|
|
WO2021076985A1
(en)
|
2019-10-16 |
2021-04-22 |
University Of Virginia Patent Foundation |
Ceramide ratios as predictive and therapeutic biomarkers for leukemias
|
|
AU2020370110A1
(en)
|
2019-10-21 |
2022-05-26 |
Rhizen Pharmaceuticals Ag |
Compositions comprising a DHODH inhibitor for the treatment of acute myeloid leukemia
|
|
CN112704679B
(zh)
|
2019-10-24 |
2023-06-06 |
沈阳药科大学 |
含高三尖杉酯碱的药物组合物及其应用
|
|
CN114901284A
(zh)
|
2019-10-29 |
2022-08-12 |
希洛斯医药品股份有限公司 |
用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
|
|
JP2022554346A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレーション |
２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
|
|
WO2021092543A1
(en)
|
2019-11-08 |
2021-05-14 |
University Of Virginia Patent Foundation |
Ceramide analog saclac modulates sphingolipid levels and mcl-1 splicing to induce apoptosis in acute myeloid leukemia
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021094827A1
(en)
|
2019-11-11 |
2021-05-20 |
Race Oncology Ltd. |
Use of bisantrene to treat measurable residual disease in acute myeloid leukemia
|
|
CN115151534B
(zh)
|
2020-02-14 |
2024-02-06 |
南京药石科技股份有限公司 |
白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法
|
|
WO2021180008A1
(zh)
|
2020-03-11 |
2021-09-16 |
暨南大学 |
含脲结构的三芳环化合物及其应用
|
|
CN111269149B
(zh)
|
2020-04-08 |
2022-04-15 |
南京优氟医药科技有限公司 |
一种5-(3,3-二甲基胍基)-2-氧代戊酸的生产工艺
|
|
CN111358952B
(zh)
|
2020-04-15 |
2022-03-15 |
中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） |
一种抗肿瘤药物组合物及其制剂和应用
|
|
CN111558044B
(zh)
|
2020-06-01 |
2022-02-11 |
中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） |
一种包含舒尼替尼的药物组合物及其制剂和应用
|
|
CN111808821B
(zh)
|
2020-06-24 |
2022-06-14 |
南方医科大学珠江医院 |
Flt3-nkg2d双靶点car-t的构建与制备
|
|
WO2022009235A1
(en)
|
2020-07-10 |
2022-01-13 |
Msn Laboratories Private Limited, R&D Center |
Process for the preparation of gilteritinib fumarate
|
|
CN111760024B
(zh)
|
2020-07-24 |
2021-12-28 |
中国药科大学 |
一种渗透增强型金纳米簇载药靶向制剂及其制法和应用
|
|
WO2022132936A1
(en)
|
2020-12-15 |
2022-06-23 |
Children's Hospital Medical Center |
Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
|
|
KR102231446B1
(ko)
|
2021-01-21 |
2021-03-24 |
(주) 와이디생명과학 |
베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
|
|
CN116847845A
(zh)
|
2021-02-12 |
2023-10-03 |
公益财团法人癌研究会 |
吉瑞替尼对于各种突变体的应用
|
|
CN115429805A
(zh)
|
2021-06-01 |
2022-12-06 |
上海交通大学医学院附属瑞金医院 |
一种抗flt3-itd耐药突变型急性髓系白血病药物
|
|
TW202317561A
(zh)
|
2021-07-01 |
2023-05-01 |
美商羅曼德生物治療公司 |
作為治療劑的具有１ｈ—吡唑并［４，３—ｃ］吡啶—６—胺基的化合物
|
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
|
WO2023043630A1
(en)
|
2021-09-16 |
2023-03-23 |
Lomond Therapeutics, Inc. |
Compounds having n-arylpyrimidin-2-amine derivatives as therapeutic agents
|
|
KR20240069783A
(ko)
|
2021-09-24 |
2024-05-20 |
더 리전츠 오브 더 유니버시티 오브 캘리포니아 |
작용제의 선택적 전달을 위한 전구약물로서의 고리형 퍼옥시드
|
|
CN113861179A
(zh)
|
2021-10-22 |
2021-12-31 |
上海应用技术大学 |
一种新型flt3激酶抑制剂及其合成与应用
|
|
WO2023116888A1
(zh)
|
2021-12-23 |
2023-06-29 |
杭州多域生物技术有限公司 |
一种五元并六元化合物、制备方法、药物组合物和应用
|
|
WO2023150601A2
(en)
|
2022-02-02 |
2023-08-10 |
Children's Hospital Medical Center |
Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
|
|
CN115710281B
(zh)
|
2022-11-14 |
2024-05-17 |
南京中医药大学 |
一种异噁唑并[5,4-b]吡啶类FLT3抑制剂及其制备方法与用途
|